"My guess is it will get back to ODAC [the Oncology Drugs Advisory Committee], and at that point, depending on who is on the ODAC committee, the reproducibility of the study will be called into question," one industry executive speculated.
Others speculate that Dendreon will also face some steep challenges before its manufacturing process for the new vaccine is approved. And the vaccine could face some heavy resistance from payers if the therapy delivers only a few months of added survival time.
If I read the benefits of the drug, it may be administered earlier in the disease with much better results, i.e., a true vaccine. There will be many other uses for this drug in addition to the specific one advanced in this P3 trial for the FDA to give it approval. You are being very short-sighted (pun intended).